Zepbound, Wegovy, or Mounjaro denied? Here's how to appeal it

The one question that decides everything

Read your denial letter and find the actual reason. There are two fundamentally different situations, and they need completely different responses.

The letter itself usually tells you which one you're facing. Language like "not medically necessary" or "criteria not met" points to a criteria denial. Language like "not a covered benefit" or "excluded under your plan" points to a formulary exclusion. If it's ambiguous, call your insurer and ask directly: does my plan cover this drug class at all, and if so, what did I fail to meet?

If it's a criteria denial, here's what actually wins

Step therapy is the most common criteria hurdle. Plans generally want documented evidence that you tried and failed other approaches, whether that's a structured diet and exercise program, or other medications, before approving a GLP-1. If your physician has already tried these with you, that history needs to be in the record explicitly, not just implied. Ask your physician's office to document, in writing, exactly what was tried, for how long, and why it didn't work or wasn't tolerated.

The other thing to check immediately: your indication. A GLP-1 prescribed for type 2 diabetes and a GLP-1 prescribed for weight loss sit under completely different coverage rules on most plans, even when it's the same drug. If your diagnosis genuinely includes diabetes and the denial treated the prescription as weight-loss-only, that's a factual error worth correcting immediately, and often the fastest possible win.

Beyond that, this follows the same playbook as any medical-necessity appeal: get the plan's specific published clinical criteria for GLP-1 coverage, and go through it point by point showing your chart meets each element. Vague appeals lose. Appeals that cite the plan's own criteria document, line by line, do much better.

If it's a formulary exclusion, be honest with yourself

This is the harder conversation, but it matters more than any appeal tactic: if your plan's contract flatly excludes weight-loss drugs as a category, an appeal that argues you personally need the medication usually doesn't change the outcome, because external reviewers are checking your case against the plan's clinical judgment, and there's no clinical judgment to challenge here. It's a benefit design decision, made when the employer or insurer built the plan.

Your realistic options in this situation look different from a normal appeal:

• Check whether a different diagnosis would put you under a covered indication instead, most commonly type 2 diabetes rather than weight management alone.
• If you're on an employer plan, talk to HR or benefits directly. Employers choose what their plan covers and can sometimes add a rider or make an exception outside the formal appeal process.
• Look into manufacturer patient-assistance programs, which exist specifically for people whose insurance won't cover these drugs.

We'd rather tell you this upfront than have you spend months on an appeal built on a foundation that doesn't hold. If your situation turns out to be a criteria denial instead once we look at the actual letter, that changes the picture entirely, and it's worth having someone check before you assume either way.

What the numbers actually say

Reliable, large-scale data specifically on GLP-1 denials is thinner than for other categories, so treat what follows as a general picture rather than a precise statistic for your situation. Reported weight-management denial rates for GLP-1s run above 50%. Appeal success rates reported across different levels of appeal range from roughly 44% to 65%. Roughly 19% to 25% of large employers report covering GLP-1s for weight loss specifically, which tells you the exclusion scenario above is genuinely common, not an edge case.

None of these figures come from a CMS or KFF-grade dataset built specifically for GLP-1s, and we're not going to dress them up as more precise than they are. What they do confirm is that denials in this category are common on both sides of the criteria-versus-exclusion line, and that a real share of appealed cases do succeed.